Interleukin-6_NN
promotes_VBZ
multiple_JJ
myeloma_NN
cell_NN
growth_NN
via_IN
phosphorylation_NN
of_IN
retinoblastoma_NN
protein_NN
._.

Interleukin-6_NN
-LRB-_-LRB-
IL-6_NN
-RRB-_-RRB-
mediates_VBZ
autocrine_JJ
and_CC
paracrine_JJ
growth_NN
of_IN
multiple_JJ
myeloma_NN
-LRB-_-LRB-
MM_NN
-RRB-_-RRB-
cells_NNS
and_CC
inhibits_VBZ
tumor_NN
cell_NN
apoptosis_NN
._.

Abnormalities_NNS
of_IN
retinoblastoma_NN
protein_NN
-LRB-_-LRB-
pRB_NN
-RRB-_-RRB-
and_CC
mutations_NNS
of_IN
RB_NN
gene_NN
have_VBP
been_VBN
reported_VBN
in_IN
up_RB
to_TO
70_CD
%_NN
of_IN
MM_NN
patients_NNS
and_CC
80_CD
%_NN
of_IN
MM-derived_JJ
cell_NN
lines_NNS
._.

Because_IN
dephosphorylated_VBN
-LRB-_-LRB-
activated_VBN
-RRB-_-RRB-
pRB_NN
blocks_VBZ
transition_NN
from_IN
G1_NN
to_TO
S_NN
phase_NN
of_IN
the_DT
cell_NN
cycle_NN
whereas_IN
phosphorylated_VBN
-LRB-_-LRB-
inactivated_VBN
-RRB-_-RRB-
pRB_NN
releases_VBZ
this_DT
growth_NN
arrest_NN
,_,
we_PRP
characterized_VBD
the_DT
role_NN
of_IN
pRB_NN
in_IN
IL-6-mediated_JJ
MM_NN
cell_NN
growth_NN
._.

Both_CC
phosphorylated_VBN
and_CC
dephosphorylated_VBN
pRB_NN
were_VBD
expressed_VBN
in_IN
all_DT
serum-starved_JJ
MM_NN
patient_NN
cells_NNS
and_CC
MM-derived_JJ
cell_NN
lines_NNS
,_,
but_CC
pRB_NN
was_VBD
predominantly_RB
in_IN
its_PRP$
phosphorylated_JJ
form_NN
._.

In_IN
MM_NN
cells_NNS
that_WDT
proliferated_VBD
in_IN
response_NN
to_TO
IL-6_NN
,_,
exogenous_JJ
IL-6_NN
downregulated_VBD
dephosphorylated_VBN
pRB_NN
and_CC
decreased_VBN
dephosphorylated_JJ
pRB-E2F_NN
complexes_NNS
._.

Importantly_RB
,_,
culture_NN
of_IN
MM_NN
cells_NNS
with_IN
RB_NN
antisense_JJ
,_,
but_CC
not_RB
RB_NN
sense_NN
,_,
oligonucleotide_NN
-LRB-_-LRB-
ODN_NN
-RRB-_-RRB-
triggered_VBD
IL-6_NN
secretion_NN
and_CC
proliferation_NN
in_IN
MM_NN
cells_NNS
;_:
however_RB
,_,
proliferation_NN
was_VBD
only_RB
partially_RB
inhibited_VBN
by_IN
neutralizing_VBG
anti-IL-6_JJ
monoclonal_JJ
antibody_NN
-LRB-_-LRB-
MoAb_NN
-RRB-_-RRB-
._.

In_IN
contrast_NN
to_TO
MM_NN
cells_NNS
,_,
normal_JJ
splenic_JJ
B_NN
cells_NNS
express_VBP
dephosphorylated_VBN
pRB_NN
._.

Although_IN
CD40_NN
ligand_NN
-LRB-_-LRB-
CD40L_NN
-RRB-_-RRB-
triggers_VBZ
a_DT
shift_NN
from_IN
dephosphorylated_VBN
to_TO
phosphorylated_JJ
pRB_NN
and_CC
proliferation_NN
of_IN
B_NN
cells_NNS
,_,
the_DT
addition_NN
of_IN
exogenous_JJ
IL-6_NN
to_TO
CD40L-treated_JJ
B_NN
cells_NNS
does_VBZ
not_RB
alter_VB
either_CC
pRB_NN
or_CC
proliferation_NN
,_,
as_IN
observed_VBN
in_IN
MM_NN
cells_NNS
._.

These_DT
results_NNS
suggest_VBP
that_IN
phosphorylated_VBN
pRB_NN
is_VBZ
constitutively_RB
expressed_VBN
in_IN
MM_NN
cells_NNS
and_CC
that_IN
IL-6_NN
further_RB
shifts_VBZ
pRB_NN
from_IN
its_PRP$
dephosphorylated_JJ
to_TO
its_PRP$
phosphorylated_JJ
form_NN
,_,
thereby_RB
promoting_VBG
MM_NN
cell_NN
growth_NN
via_IN
two_CD
mechanisms_NNS
;_:
by_IN
decreasing_VBG
the_DT
amount_NN
of_IN
E2F_NN
bound_VBN
by_IN
dephosphorylated_VBN
pRB_NN
due_JJ
to_TO
reduced_VBN
dephosphorylated_VBN
pRB_NN
,_,
thereby_RB
releasing_VBG
growth_NN
arrest_NN
;_:
and_CC
by_IN
upregulating_VBG
IL-6_NN
secretion_NN
by_IN
MM_NN
cells_NNS
and_CC
related_JJ
IL-6-mediated_JJ
autocrine_JJ
tumor_NN
cell_NN
growth_NN
._.

